Sequence: WRAP5 + transferrin ligand
| Experiment Id | EXP002236 |
|---|---|
| Paper | Circadian-Tuned Peptide Drug/Gene Co-Delivery Nanocomplexes to Enhance Glioblastoma Targeting and Tr |
| Peptide | Tf-WRAP5 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 1 µg pDNA |
| Mixing Ratio | N/P = 1 |
| Formulation Format | targeted CPP–pDNA nanocomplex |
| Formulation Components | TMZ/Tf-WRAP5/pDNA |
| Size Nm | 183.00 |
| Zeta Mv | 11.90 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U87 glioblastoma cells |
| Animal Model | |
| Administration Route | |
| Output Type | gene expression |
| Output Value | enhanced p53 mRNA and protein expression |
| Output Units | |
| Output Notes | TfR-mediated uptake; circadian optimization |
| Toxicity Notes | biocompatible |
| Curation Notes |